Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Guggenheim raised its price target on Soleno Therapeutics Inc. (NASDAQ:SLNO) to $106.00 from $97.00 on Thursday, while maintaining a Buy rating on the stock following strong VYKAT sales. The stock, currently trading at $81.19, has delivered an impressive 84.69% return over the past year, according to InvestingPro data.
The company reported VYKAT sales of $32.7 million, which was within its preannounced range of $31 million to $33 million and exceeded earlier consensus estimates.
Guggenheim noted that initial monitoring requirements may present the greatest burden early in the product launch as clinics develop algorithms to start patients on the drug.
The firm highlighted that Soleno’s sales force is employing a two-pronged approach to facilitate patient starts by targeting both physicians and patient advocates, while attitudes regarding response and compliance are gradually changing with increased utilization.
Despite potential modest impacts from the holiday season on start forms, Guggenheim expects robust VYKAT uptake during the second half of 2025, as most clinics are likely to be prepared to handle demand. Analyst consensus remains strongly bullish, with targets ranging from $100 to $145. Get deeper insights and access to 12 additional ProTips for SLNO with InvestingPro’s comprehensive research report.
In other recent news, Soleno Therapeutics reported its earnings for the second quarter of 2025, significantly exceeding expectations. The company posted an earnings per share (EPS) of -$0.09, surpassing the forecasted -$0.64, which resulted in a surprise of 85.94%. Revenue also reached $32.7 million, more than doubling the anticipated $15.35 million, with a surprise of 113.03%. These results highlight a robust financial performance for Soleno Therapeutics. Despite the positive earnings and revenue results, the company’s stock experienced a minor decline in after-hours trading. There were no recent reports of mergers or acquisitions involving Soleno Therapeutics. Additionally, there have been no recent analyst upgrades or downgrades reported for the company. These developments are noteworthy for investors keeping an eye on Soleno Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.